

Ref: FOI/CAD/ID 3557

Please reply to:
FOI Administrator
Trust Management
Service Centre
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

03 October 2016

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Multiple Sclerosis.

In your trust how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 6 months, latest 6 months that you can provide?

Please provide the number of patients by treatment for the following disease modifying drugs.

Aubagio (Teriflunomide)
Avonex (interferon beta-1a)
Betaferon (interferon beta-1b)
Copaxone (Glatiramer acetate)
Extavia (beta interferon-1b)
Gilenya (Fingolimod)
Lemtrada (Alemtuzumab)
Rebif (beta interferon-1a)
Tecfidera (dimethyl fumarate)
Tysabri (Natalizumab)
Ampyra (Fampyra)
Peginterferon beta-1a (Plegridy)
Daclizumab (Zinbryta)
Others

The following table contains figures for June, July and August 2016. The figures for previous months can be found on the Trust's website using the following link: <http://www.mtw.nhs.uk/freedom-of-information/>

Aubagio	3 patients
Avonex	2 patients
Betaferon	0 patients
Copaxone	3 patients

Extavia	0 patients
Gilenya (Fingolimod)**	3 Patients
Rebif	0 Patients
Tecfidera.	6 patients
Plegridy	1 patient

** This figure is based on all patients across the Trust who have received a delivery of medication from June to August.